MeMed

MeMed has developed the first FDA-cleared host immune response diagnostic assay—MeMed BV®—which distinguishes between bacterial and viral infections within 15 minutes using a compact device. Real-world studies show that use of this test reduces unnecessary antibiotic prescriptions by up to 63%, outperforms standard care, optimizes antibiotic stewardship, lowers healthcare costs, and improves patient management across urgent care settings globally. The company’s pipeline includes the investigational “MeMed Severity” test designed to predict risk of deterioration or mortality in patients with suspected sepsis or acute infection; this has received FDA Breakthrough Device Designation but is not yet commercially available.